What is the latest price of Tocilizumab 400mg?

Tocilizumab is a monoclonal antibody drug targeting the interleukin-6 receptor (IL-6R), which plays an important role in the treatment of rheumatic diseases and severe inflammation. Its main indications include moderately to severely active rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (sJIA), adult Still's disease (AOSD), etc. In addition, tocilizumab has also shown significant immunomodulatory value in COVID-19-related cytokine storm and CAR-T therapy-induced cytokine release syndrome (CRS), and has been included in emergency treatment recommendations by health departments in many countries.

In China, tocilizumab, as an imported original drug, has been introduced by Roche and approved for marketing, and has been successfully included in the national medical insurance drug catalog, significantly reducing the financial burden on patients. Common specifications on the market include80mg, 200mg, and 400mg, of which 400mg is one of the main dosage forms used for intravenous infusion treatment. It is understood that the price range after medical insurance reimbursement is between several thousand yuan. The specific price varies slightly depending on local reimbursement ratios and hospital channels. Without reimbursement, the price of 400mg imported version of the original research may be as high as about 10,000 yuan.

In overseas markets, the price of tocilizumab is relatively transparent. For example, in the United States or Europe, 400mg is priced around one thousand US dollars. In some countries, the actual amount paid by patients is lower due to different medical insurance coverage ratios. It should be noted that the price is not only related to the dose, but also to the frequency of treatment, patient weight and concomitant medications. Therefore, in actual use, the doctor should formulate a reasonable treatment plan based on the specific condition.

As the localization of biologics advances, more biosimilars of tocilizumab may be launched in the future, further reducing costs and improving accessibility, making it a very important first-line treatment option in the field of immune rheumatism.

Reference materials:https://www.drugs.com/mtm/tocilizumab.html